Sage Therapeutics said on Tuesday it will discontinue the development of its Alzheimer's disease drug as it did not meet the ...

The pipeline setbacks related to SAGE's neurology candidate, SAGE-324, being developed for essential tremor, weigh heavily on ...

Tuesday, Sage Therapeutics, Inc. (NASDAQ:SAGE) released topline results from the Phase 2 LIGHTWAVE study to evaluate the ...

Sage Therapeutics Inc.’s stock tumbled 12.8% early Tuesday, after the company said a mid-stage trial of a treatment for mild ...

Needham analyst Ami Fadia has reiterated their neutral stance on SAGE stock, giving a Hold rating today. Ami Fadia has given his Hold rating ...

(RTTNews) - Sage Therapeutics, Inc. (SAGE) Tuesday said its Phase 2 LIGHTWAVE study to evaluate dalzanemdor in participants with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's ...

Sage Therapeutics has seen another clinical trial go up in smoke. | Sage Therapeutics has seen another clinical trial go up ...

Sage Therapeutics said on Tuesday it would discontinue the development of its experimental drug for Alzheimer's disease as it ...

Sage Therapeutics shares fell more than 10% in premarket trading Tuesday after the latest setback for the biopharmaceutical company's dalzanemdor drug candidate. Shares of Sage, which closed Monday at ...

Fintel reports that on October 4, 2024, RBC Capital downgraded their outlook for Sage Therapeutics (NasdaqGM:SAGE) from ...

Sage said it will continue to test dalzanemdor as a treatment for Huntington's disease and expects to report its mid-stage ...

The biopharmaceutical company isn’t planning further clinical development of dalzanemdor to treat Alzheimer’s.